2 min read
Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics
Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen
Admin
.png?width=1800&height=600&name=MicrosoftTeams-image%20(82).png)
3 min read
Selexis SA and Turgut Pharmaceuticals Advance Partnership with Third Commercial License Agreement
Admin: Dec 20, 2017 12:00:00 AM
Supports Advancement of Biosimilar to Treat Two Ultra-Rare Diseases Geneva, Switzerland, and Istanbul, Turkey, 20 December 2017 – Selexis SA and…
3 min read
Selexis SA and Pelican Therapeutics Sign Agreement to Advance Pelican’s Immunotherapy Clinical Programs
Admin: Oct 4, 2017 12:00:00 AM
Selexis to Develop High-performance Research Cell Banks to Expedite the Manufacturing of Immunotherapy Clinical Candidates Designed to Target Cancers…
5 min read
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
Admin: Sep 26, 2017 12:00:00 AM
Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE…
1 min read
Selexis Announces Commercial License Agreement with Takeda for the Development of Fusion Proteins
Admin: Jun 27, 2017 12:00:00 AM
Geneva, Switzerland, 27 June 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology,…
2 min read
Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer
Admin: Jun 12, 2017 12:00:00 AM
Geneva, Switzerland and Menlo Park, CA, 12 JUNE 2017 – Selexis SA and TeneoBio, Inc. announced today that they have entered into a service agreement…
2 min read
Merck KGaA, Darmstadt, Germany Licenses Selexis SUREtechnology Platform for Immuno-Oncology Antibody Program
Admin: May 30, 2017 12:00:00 AM
Geneva, Switzerland, 30 MAY 2017 – Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology,…
4 min read
Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist
Admin: May 23, 2017 12:00:00 AM
Geneva, Switzerland, and Nantes, France, 23 May 2017 – Selexis SA and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) announced today the…
1 min read
Selexis to Develop Cell Lines for Three Sanofi Biologics Programs Using Selexis SUREtechnology Platform™
Admin: Feb 21, 2017 12:00:00 AM
Selexis SA Inks Agreement for Applications in Cancer and Infectious Disease Selexis to develop cell lines for three Sanofi biologics programs using…
5 min read
Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
Admin: Nov 15, 2016 12:00:00 AM
Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases